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1  | INTRODUC TION
Systemic sclerosis (SSc) is an autoimmune idiopathic connective 
tissue disease in which there are vascular pathology, inflammation, 
dysregulated cytokines and fibrosis.[1,2] SSc has the highest mortality 
rate of all the rheumatic diseases with a 10-year mortality rate of 
23%-45%.[3] The disease predominantly affects women and depend-
ing on severity is classified as limited (confined to a single area) or 
diffuse, in which the fibrosis is widespread.[4,5] Although inflamma-
tion is key in the disease, the activation of the fibroblasts from a 
quiescent to an activated myofibroblast is considered a major patho-
genic event in the pathogenesis of the disease. These myofibroblasts 
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Abstract
Background: Systemic sclerosis is an autoimmune skin disease which is associated 
with inflammation and resulting skin fibrosis. Myofibroblasts are the key cell type 
associated with the fibrosis but how they are differentiated is not clear. DKK-1 is a 
Wnt antagonist that blocks Wnt-mediated fibrosis and is reduced in fibrotic condi-
tions. Thus, DKK-1 is a clear negative regulator of fibrosis in systemic sclerosis and 
its regulation is unknown. The aim of this work is to determine the levels of DKK-1 in 
serum and tissues of SSc and its regulation.
Methods: Skin biopsies were taken from early diffuse systemic sclerosis patients and 
healthy controls and DKK-1 measured by ELISA; serum was also isolated and DKK-1 
quantified. DKK-1 was also measured by qRT-PCR. MicroRNA33a-3p was measured 
by TaqMan PCR. miR mimics and controls were transfected into dermal fibroblasts. 
Bleomycin mouse model was employed and compared to vehicle control treated mice, 
and gene expression was employed for DKK-1 and various extracellular matrix genes.
Results: DKK-1 is reduced in SSc skin and fibroblasts but is not reduced in the circula-
tion in patients. MicroRNA33a-3p regulates DKK-1 levels epigenetically and is signifi-
cantly reduced in SSc cells and whole tissue. DKK-1 is also reduced in the bleomycin 
mouse model and pro-fibrotic genes elevated.
Conclusion: DKK-1 is reduced in SSc cells and is regulated by miR33a-3p, and restor-
ing DKK-1 levels through epigenetic means could be a therapeutic target in systemic 
sclerosis.
K E Y W O R D S
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secrete copious amounts of extracellular matrix primarily collagen 
and fibronectin and adapt a contractile phenotype that contracts 
the tissue, regardless of which organ is affected.[6,7] It is suggested 
that over half of all deaths in the developed world has a fibrotic 
component.
Although our understanding of the pathogenesis of the disease 
has substantially increased in the past few years, what governs the 
activation of the fibroblast remains unknown.[1] In recent times, the 
Wnt pathway has been identified as being a primary player in the dis-
ease.[8,9] The Wnt pathway is a development pathway that is critical 
in organ development and is highly expressed early in development 
then suppressed. Reactivation of development pathways such as the 
Wnt pathway in fibrotic diseases has recently been identified, and 
specific Wnt ligands are upregulated in SSc blood and skin tissue.[10] 
Beta-catenin which is considered a terminal part of the Wnt pathway 
is upregulated in SSc skin and lungs and localised primarily in the 
nucleus where it activates specific pro-fibrotic genes.[11,12] Indeed, 
overexpression of β-catenin in fibroblasts exacerbates bleomy-
cin-induced fibrosis.[13] The Wnt pathway consists of the ligands that 
activate specific cell-surface receptors to initiate a response that re-
cruits axin to the cell membrane and mediates the destabilisation of 
the β-catenin destruction complex, and β-catenin can then enter the 
nucleus and activate target genes. The pathway is also composed of 
a set of antagonists that can block specific Wnt signalling by trapping 
the ligand-receptor interaction or directly blocking the Wnt co-re-
ceptor.[14] It was found that one secreted Frizzled-related protein-1 
(sFRP-1) is downregulated in SSc fibroblasts and is regulated by DNA 
methylation, and we also demonstrated this.[15] One other antago-
nist Dickkopf-1 (DKK-1) has also been found to be reduced in SSc 
cells.[15] The aim of this study was to ascertain the levels of DKK-1 in 
serum of diffuse SSc patients and the levels of DKK-1 in fibroblasts 
and its regulation.
2  | MATERIAL S AND METHODS
Sixteen patients with early diffuse systemic sclerosis were recruited 
along with 16 gender-matched controls. All SSc patients fulfilled the 
new American College of Rheumatology/European League Against 
Rheumatism criteria for SSc;[16] 12 patients had anti-Scl-70 antibod-
ies, and 4 had anti-RNA polymerase antibodies; and all had given 
informed consent, and this had been given institutional ethical ap-
proval. Female patients with early diffuse were 13 and 3 male early 
diffuse SSc, and mean age was 65. Serum was isolated after 20 mL 
of blood was removed by venepuncture. This was stored at −80°C 
until used for the ELISA.
DKK-1 was measured using a specific ELISA (R&D systems, UK) 
following the manufacturer's protocol and after development was 
read on a plate reader (Tecan) at 470 nm.
Skin biopsies were taken from lesions on the forearm using the 
punch biopsy 4 mm from 5 individual patients. The tissue was di-
vided into two pieces; one was placed in TRIzol (Invitrogen), and 
RNA was isolated using manufacturer's instructions. The other piece 
was placed into tissue culture for isolated fibroblasts to grow out. 
These were all used at between passages 3 and 7 and cultured in 
Dulbecco's modified Eagle's media (DMEM) (Sigma, UK) + 10% 
(v/v) fetal calf serum supplemented with penicillin (100 U/mL) and 
streptomycin. Prior to any treatments, the cells were switched to se-
rum-free DMEM the previous night and then cultured with or with-
out Lipopolysaccharide (LPS) (1 ng/mL) (Invitrogen).
Healthy dermal fibroblasts were seeded into a twenty-four-
well plate at 5 × 104 cells per well, and left to adhere overnight. 
Cells were then transfected with microRNA mimic miR33a-3p 
(Applied Biosystems) or scramble control at 75 nmol/L for 48 hours 
using HiPerFect transfection reagent (Qiagen), by mixing 75 nm 
with 5 µL of HiPerFect transfection reagent per well (of 24-well 
plate) and mixed and left at room temperature for ten minutes 
after which this was added to individual wells. After 48 hours 
post-transfection, media were removed and DKK-1 was mea-
sured by ELISA. Also, alpha-Smooth muscle was quantified by 
qPCR using specific primers: 5′-CAGGGAGTAATGGTTGGAAT-3′ 
(forward) and 5′-TCTCAAACATAATCTGGGTCA-3′ (reverse);18S 
5′-CGAATGGCTCATTAAATCAGTTATGG-3′ (forward) and 
5′-TATTAGCTCTAGAATTACCACAGTTATCC-3′ (reverse), using 
SYBR green (Sigma) and normalised to 18S. Data are shown as fold 
change compared to scramble controls. Soluble collagen was mea-
sured in the cell supernatant by Sircol assay (Bicolour,) as previously 
described.[17]
Isolated healthy control and SSc dermal fibroblasts were cul-
tured, and then, RNA was harvested less than passage 3 using Qiagen 
miRneasy kits. qPCR was performed with TaqMan microRNA assay 
for miR33a-3p (id 4738831_miR) and normalised to housekeeping 
RNU44 (id 001094). Four individual donors were used, and all ran 
in triplicate.
qRT-PCR was performed on whole skin biopsies for DKK-1 using 
the primers human DKK-1:5′-GACTGTGCCTCAGGATTGTGT-3′ 
(forward), 5′-CAGATCTTGGACCAGAAGTGTCT-3′ (re-
verse). Axin-2:5′-CATGACGGACAGCAGTGTAGA-3′ (forward), 
5′-TACTGCCCACACGATAAGGAG-3′ (reverse). Axin-2, forward 5′-
CGG GAG CCA CAC CCT TC-3′ and reverse 5′-TGG ACA CCT GCC 
AGT TTC TTT-3′18S: forward 5′-GAA TGG CTC ATT AAA TCA GTT 
ATG G-3′, reverse 5′-TAT TAG CTC TAG AAT TAC CAC AGT TAT 
CC-3’ using SYBR green (Sigma, UK), from 1 µg of RNA. Data were 
normalised to the housekeeping gene 18S, and relative expression 
was quantified using the delta-delta CT method.[18]
SSc dermal fibroblasts from 4 donors were transfected with 
scramble or antagomiR to miR33a-3p (100 nmol/L) (Applied 
Biosystems) using HiPerFect transfection reagent as described 
above. After 46 hours, cells were lysed in RIPA buffer contain pro-
tease inhibitors and total protein assay was performed. 40 µg of 
total protein was subjected to sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis at 120 V. This was subjected to transfer 
to nitrocellulose membrane and probed with collagen 1 (Abcam) 
at 1:1000 dilution overnight, and then, anti-mouse secondary an-
tibody HRP linked was added at 1:10 000 dilution and then ex-
posed for 1 minute. The same blot was stripped and reprobed 
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with β-actin (Cell Signaling) at 1:10 000 dilution for equal load-
ing. Conditioned media from these scramble or antimiR33a-3p 
transfected cells were removed, and a TGF-β1 ELISA was used to 
quantify TGF-β1 (Quantikine, R&D systems) from four donors. All 
reactions were run in quadruplicate.
Bleomycin induced dermal fibrosis by subcutaneous injec-
tion for 4 weeks and was carried out as previously described.[2] 
Subcutaneous injections of 0.9% saline served as a vehicle con-
trol. All studies were performed with full ethical approval and 
under a UK home office licence. Four animals per group were 
used, and at the end of the experiment, skin biopsies were taken 
and placed in TRIzol. RNA was isolated using the manufacturer's 
instructions and cDNA synthesised. qRT-PCR was performed for 
with these primers: mouse collagen1A1 forward 5’-GAA GCA CGT 
CTG GTT TGG A-3’, reverse 5’-ACT CGA ACG GGA ATC CAT C-3’; 
α-SMA: forward 5′-ATGCCTCTGGACGTACAACTG-3′, reverse 
5′-CACACCATCTCCAGAGTCCA-3′; Axin-2 Forward: 5′-GAG TAG 
CGC CGT GTT AGT GAC T −3′; Reverse: 5′-CCA GGA AAG TCC 
GGA AGA GGT ATG −3′); TIMP-1 forward: 5’-GAC TAA GGC CTG 
TAG CTG TGC-3’; Reverse 5’-CTC GTT GAT TTC GGG GAA C-3’. 
qPCR was performed using SYBR green, and data were normalised 
to 18S housekeeping gene and relative expression quantified.
Mouse DKK-1 was measured by ELISA (R&D systems) following 
the manufacturer's instructions four mice per group and each mouse 
serum sample was run in quadruplicate.
Bleomycin treated mice and saline vehicle control treated mice 
were sacrificed at the end of 28 days skin biopsies were taken for 
haematoxylin and eosin (H&E) staining. Briefly, the tissue was fixed 
in formaldehyde. This was then placed in paraffin wax. Sections 
were cut at 5 µm thick, deparaffinised and stained with H&E and de-
hydrated and imaged using a light microscope at X20 magnification.
Statistical analysis was performed using Student's t test with P 
value equal or <.05 considered significant.
3  | RESULTS
The levels of serum DKK-1 in SSc diffuse patients were measured by 
ELISA and found to be not significantly different compared to healthy 
control patients (2.26 ng/mL SD = 0.08 vs 2.45 ng/mL SD = 0.096, 
n = 16 non-significant, P = .151 Student's t test; Figure 1).
We next examined the mRNA expression of DKK-1 in whole skin 
biopsies in SSc patients versus healthy controls and found that sig-
nificantly reduced levels of DKK-1 in SSc skin compared to controls 
normalised to 18S mRNA 1 vs 0.44 HC v SSc P = <.0001 (n = 5; 
Figure 2A). Furthermore, culturing SSc dermal fibroblasts from the 
same tissue revealed significantly reduced DKK-1 levels in con-
ditioned medium compared to control 2.45 ng/mL (SD = 0.41) vs 
1.51 ng/mL (SD = 0.32) (P = .011 Student's t test; n = 4, Figure 2B).
Within the same skin biopsies, the levels of the Wnt target gene 
Axin-2 were significantly elevated compared to healthy controls 
(Figure 3A, 6.1 fold change SD = 0.4 5 vs 1.1 fold change, SD = 0.002, 
P = .001; n = 5 Student's t test).
To examine what may be leading to the significant downregu-
lation of DKK-1 in dermal fibroblasts, we incubated normal healthy 
dermal fibroblasts with the known fibrotic stimulator the TLR4 ago-
nist LPS. However, incubation with LPS did not lead to a significant 
downregulation of DKK-1 expression (1.1 fold change treated vs 1 
fold untreated; n = 4).
To examine if epigenetic regulation of DKK-1 is operative, we 
examined bioinformatically if DKK-1 can be targeted by microR-
NAs. Targetscan suggested that microRNA33a-3p can directly 
target DKK-1 leading to repression by binding to the 3’UTR, and 
Figure 3B demonstrates based on in silico analysis the binding site 
of miR33a-3p and positions 231-237 of DKK-1 3’UTR (bases in bold 
and underlined). Thus, transfection of miR33a-3p into normal der-
mal fibroblasts led to a significant reduction of DKK-1 expression 
(1.58 ng/mL SD = 0.03 vs 1 ng/mL SD = 0.04, n = 4, P = <.001 signif-
icant difference Student's t test; Figure 3C). Indeed, transfection of 
miR33a-3p into dermal fibroblasts leads to a significant increase in 
collagen release compared to concentration matched control mimics 
(P = .0002 significant difference Student's t test n = 4; Figure 3D). 
We also measured the expression of the myofibroblast marker al-
pha-smooth muscle actin and found this was not changed signifi-
cantly (P = >.05 Student's t test; n = 4; Figure 3E). We next examined 
in isolated dermal fibroblasts from SSc patients and healthy controls 
the expression of miR33a-3p using TaqMan assays. We found that 
miR33a-3p is significantly elevated compared (3.3 fold) to healthy 
controls (P = .003; n = 4; Figure 3F).
Knowing that miR33a-3p is elevated in SSc patients’ dermal fi-
broblasts and possibly targeting DKK-1 to mediate fibrosis, we used 
an anti-miR to miR33a-3p in SSc dermal fibroblasts to determine if 
this blockade would reduce collagen. Figure 4A indicates that an-
ti-miR33a-3p reduced collagen 1 expression in these cells compared 
to scramble controls. However, no change in TGF-β1 levels was 
found after miR33a-3p inhibition (1.86 SD 0.11 vs 1.83 SD 0.17 ng/
mL, P = .8 Student's t test, n = 4 Figure 4B).
F I G U R E  1   Serum DKK-1 is not significantly different in SSc 
patients. Serum DKK-1 was measured using ELISA in both healthy 
controls (HC) and SSc patients. No significant difference was 
observed, P = .151 Student's t test, n = 16. Main bar is the mean 
and SD
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Finally, using the bleomycin model of skin fibrosis (Figure 5A), 
which is an inflammation-driven model, we could see that the 
whole skin gene expression levels of DKK-1 were reduced com-
pared to vehicle treated mice 1.02 (SD = 0.02) vs 0.62 (SD = 0.05) 
fold change Vehicle v bleomycin treated (P = .0003; Student's t 
test n = 4; Figure 5B). Also, several pro-fibrotic genes were also 
significantly upregulated (Table 1). However, analysis of serum 
levels of DKK-1 demonstrated no significant difference (vehicle 
F I G U R E  2   DKK-1 in skin tissue and fibroblasts is significantly reduced in SSc.(A) Whole skin biopsies were taken and analysed by qRT-
PCR for DKK-1 expression and normalised to 18S. *Significantly reduced DKK-1 compared to HC, P = <.001 Student's t test, n = 5. (B) SSc 
dermal fibroblasts have significantly reduced DKK-1 levels. This was measured by ELISA and compared to HC, P = .011 Student's t test, n = 4
F I G U R E  3   Wnt target gene Axin-2 is increased in SSc. (A) Whole skin biopsies were excised and measured for Axin-2 by qRT-PCR and 
normalised to 18S. *Significant difference compared to HC, P = .001 Student's t test, n = 5. Main bar is the mean and SD (B) Targetscan 
predicted binding sites of positions 231-237 of 3’UTR of DKK-1 and miR33a-3p. Bases are in boldface and underlined. (C) Transfection of 
miR33a-3p leads to reduced DKK-1 levels. Healthy dermal fibroblasts were transfected with miR33a-3p mimic (75 nmol/L) or matched 
scramble miR, and after 48 h, DKK-1 was quantified. * significant difference compared to controls, P = <0.001 Student's t test, n = 4. (D) 
Collagen was quantified by Sircol assay after transfection with miR33a-3p mimic or matched scramble control miR. * significant difference 
compared to scramble, P = .0002 Student's t test, n = 4 (E) Alpha-smooth muscle actin was quantified by qPCR after transfection with 
miR33a-3p mimic or scramble controls. Data are mean and SD and from 4 independent experiments. F, Elevated miR33a-3p in SSc 
fibroblasts. SSc isolated fibroblasts were quantified for miR33a-3p along with controls by qPCR. Data are normalised to RNU44 and shown 
as fold change compared to healthy controls. * significant difference compared to control, P = .003 Student's t test, n = 4
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1.2 ng/mL SD = 0.26 vs 1.29 ng/mL SD = 0.16, P = .77; Mann-
Whitney U test n = 4 mice per group; Figure 5C).
4  | DISCUSSION
This study addressed whether the Wnt antagonist DKK-1 is reduced 
in SSc serum and skin. Surprisingly, we found that there was no re-
duction in the levels of DKK-1 in the sera of SSc patients. We had 
predicted that there would be a reduction in DKK-1 levels in the 
blood as this is an extracellular protein that mediates its effects via 
blocking Wnt signalling.
However, lower levels of DKK-1 were found in skin and iso-
lated dermal fibroblasts from SSc patients. This is in keeping with 
the fact that the Wnt bona fide target gene Axin-2 is elevated 
in SSc cells also, indicating enhanced Wnt signalling in SSc.[13] It 
is known that Wnt signalling is important in tissue development 
but it is also been demonstrated to be elevated in SSc (7) and its 
inhibition reduces fibrosis in vivo animal models.[8,19] DKK-1 me-
diates its effects via binding to the Wnt accessory receptor LRP6, 
[14,20] and this leads eventually to β-catenin inhibition. We found 
reduced levels of DKK-1 in isolated dermal fibroblasts but not in 
the serum of SSc patients. To examine if Toll-like receptor signal-
ling could reduce the levels of DKK-1, we incubated with LPS and 
could find no alteration in the levels of DKK-1. LPS is known to be 
pro-fibrotic in dermal fibroblasts.[1]
We sought to identify if DKK-1 can be regulated epigenetically 
as methylation of DKK-1 has previously been described,[15] and epi-
genetics is now thought to play a key role in SSc pathogenesis.[21,22] 
Using bioinformatics, we could find a putative binding site in DKK-1 for 
miR-33a-3p. MicroRNAs are small non-coding RNA that regulate gene 
expression at the post-transcriptional level by binding the 3’UTR of their 
target genes, and many microRNAs are dysregulated in SSc,[21,23,24] 
impacting on multiple processes. We could find that transfection of 
F I G U R E  4   AntimiR reduced collagen in SSc fibroblasts. (A)Western blot from two independent donors early diffuse SSc after 
transfection with anti-miR33a or scramble controls. Top blot is collagen1 and β-actin is the loading control. C = scramble controls; 
A = antimiR-33a-3p. (B) TGF-β1 was quantified by ELISA in media of SSc cells after scramble or antimiR33a-3p transfection. No significant 
difference; Student's t test, n = 4
F I G U R E  5   DKK-1 is reduced in 
the bleomycin model of fibrosis. (A) 
Representative H&E sections of whole 
skin left panel are vehicle control and 
right panel is bleomycin-treated skin. 
Magnification is X20. (B) Whole skin from 
mice exposed to bleomycin or vehicle 
control was analysed for DKK-1 by qRT-
PCR. * significantly different compared 
to vehicle, P = .0003 (n = 4). (C) Serum 
DKK-1 levels are not significantly different 
in the bleomycin model of fibrosis. Serum 
DKK-1 was measured by specific ELISA 
after bleomycin or vehicle injection. No 
significant difference is evident across 
groups, P = .771; Mann-Whitney U test 
(n = 4)
(A)
(C)(B)
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miR-33a-3p led to significant reductions in DKK-1 levels and also in-
creased collagen release, suggesting that DKK-1 is a direct target of mi-
R33a-3p. We, however, saw no change in alpha-smooth muscle actin 
expression. Transfection of anti-miR33a-3p into dermal fibroblasts to 
block miR-target interactions led to reduced collagen 1 expression in 
these cells. However, secreted TGF-β1 was not significantly different 
suggesting that this is independent of TGF-β pathways. We did not con-
firm that DKK1 is a direct target of miR33a-3p as we did not perform the 
3’UTR luciferase assay; however, this is predicted to bind using bioinfor-
matic analysis. miR33 is a critical microRNA that regulates cholesterol 
levels and is encoded within introns of sterol regulatory elements.[25-27] 
MicroRNA33-deficient mice are protected from experimental cardiac 
fibrosis,[28] and hepatic stellate cells, the myofibroblasts of the liver, 
have significantly elevated miR33.[29] Interestingly, microRNA-deficient 
mice have significantly reduced kidney fibrosis and application of a mi-
croRNA33 inhibitor reduced renal fibrosis in vivo,[30] suggesting this 
could be a therapeutic in SSc. We also demonstrated significantly ele-
vated levels of miR33a-3p in SSc isolated fibroblasts compared to con-
trols. What is regulating the increased miR33a-3p levels is not known; 
however in hepatic stellate cells, stimulation with TGF-β1 increased 
miR33a levels.[31] Elevated miR33a-3p levels may be used as a possible 
biomarker of disease given its direct association with DKK1 levels in 
dermal fibroblasts. Although caution must be used as the sample size 
here is small and conclusions regarding a possible biomarker need fur-
ther validation in larger cohorts. Biomarkers in SSc are badly needed to 
help guide clinical decision-making.
We also confirmed that DKK-1 was reduced in an animal 
model of fibrosis, the bleomycin model along with pro-fibrotic 
genes including collagen and the Wnt target gene Axin-2. This is 
an inflammatory-mediated model of skin fibrosis and therefore 
suggests that inflammation, at least in the bleomycin model, could 
possibly be driving the reduction in DKK-1 expression. Analysis 
of sera from bleomycin mice revealed no significant differences 
between bleomycin treatment and vehicle control, which mir-
rors what we see in the SSc patients. Cell-intrinsic reductions in 
DKK-1 could be mediated epigenetically through a loop contain-
ing miR33a-3p.
4.1 | Conclusions
In conclusion, we demonstrate that the Wnt antagonist DKK-1 is re-
duced in skin and isolated cells but not serum of SSc patients and that 
in dermal fibroblasts this is regulated epigenetically by miR33a-3p. 
Strategies that reduce this microRNA could reduce Wnt signalling 
and fibrosis. Furthermore, miR33a-3p could be a possible biomarker 
in SSc skin.
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